Companies › Shanghai AbelZeta
4 active drug programs in 5 registered trials: 5 Phase 1; Oncology; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| A-CAR032 dnTGFβRII-armoured STEAP2-targeted CAR T cell therapy | STEAP2 | Phase 1 | Prostate Cancer | Jan 2027 |
| Prizloncabtagene autoleucel 4-1BB bispecific CAR-T cell targeting CD19 and CD20 | CD19, CD20 | Phase 1 | Relapsed/Refractory Large B-Cell Lymphoma | Mar 2027 |
| C-CAR031 Armored and GPC3-targeted autologous CAR T-cell therapy | – | Phase 1 | Squamous Cell Lung Cancer; Hepatocellular Carcinoma | Apr 2027 |
| C-CAR088 BCMA-directed CAR-T cell therapy | BCMA | Phase 1 | Multiple Myeloma | Jul 2037 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07344311 | A-CAR032 | Phase 1 | Prostate Cancer | Oncology | Jan 2027 |
| NCT05800977 | Prizloncabtagene autoleucel | Phase 1 | Relapsed/Refractory Large B-Cell Lymphoma | Oncology | Mar 2027 |
| NCT07444281 | C-CAR031 | Phase 1 | Squamous Cell Lung Cancer | Oncology | Apr 2027 |
| NCT06590246 | C-CAR031 | Phase 1 | Hepatocellular Carcinoma | Oncology | Apr 2030 |
| NCT05521802 | C-CAR088 | Phase 1 | Multiple Myeloma | Oncology | Jul 2037 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.